Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. The company's lead product candidate is ersodetug, a human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 2 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Rezolute Inc.

In a report released on June 2, Matt Hewitt from Craig-Hallum maintained a Hold rating on Rezolute. The company’s shares closed yesterday at $4.00....

Craig-Hallum Keeps Their Hold Rating on Rezolute (RZLT)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Rezolute (RZLT) and Relay Therapeutics (RLAY) with b...

Analysts Are Bullish on These Healthcare Stocks: Rezolute (RZLT), Relay Therapeutics (RLAY)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aveanna Healthcare Holdings (AVAH) and Rezolute (RZL...

Current Quarter	$-0.13	Next Quarter	$-0.13
Current Year	$-0.69	Next Year	$-0.48
QoQ Growth	+0.0%	YoY Growth	+30.4%
3Y EPS CAGR	N/A	Target Price	$7.11
Consensus	Buy	Upside	+41.6%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RZLT	$5.02	+4.80%	2.81M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RZLT	$5.02	+4.8%	2.81M
3
4
5
6

RZLT

RZLT

EPS Estimates Overview

Quarterly EPS Estimates

Revenue Analysis

Get Rezolute Inc. Data in Excel

Get Rezolute Inc. Data in Excel